Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SynVitro Cumulase
- Development stage
- Unknown
- Lead developer
- Halozyme
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Ex Vivo
01
Overview
SynVitro Cumulase is a specialized formulation of recombinant human PH20 hyaluronidase (rHuPH20) designed for use in assisted reproductive technology (ART). Developed through a collaboration between Halozyme Therapeutics and MediCult (now part of CooperSurgical), it received FDA 510(k) clearance in 2006 as the first recombinant hyaluronidase product for in vitro fertilization (IVF). The product is used to facilitate the removal of the cumulus-oocyte complex and corona radiata surrounding the oocyte prior to intracytoplasmic sperm injection (ICSI). It works by enzymatically degrading hyaluronic acid, the primary component of the extracellular matrix between cumulus cells. As a recombinant human protein, SynVitro Cumulase offers a high degree of purity and eliminates the risks of pathogen transmission and immunogenicity associated with traditional animal-derived (bovine or ovine) hyaluronidase extracts.
- Brand names
- SynVitro Cumulase
- Other names
- recombinant human PH20 hyaluronidaserHuPH20rHuPH-20rHuPH 20
Beyond the preview
Go deeper on SynVitro Cumulase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SynVitro Cumulase.